DA-1726

Overview

DA-1726 is an investigational oxyntomodulin-analogue peptide developed by MetaVia Inc. (Nasdaq: MTVA) as a once-weekly subcutaneous dual agonist at the glucagon-like peptide-1 receptor (GLP-1R) and the glucagon receptor (GCGR). It is engineered to combine the appetite-suppressing and glycemic effects of GLP-1 receptor activation with the energy-expenditure and hepatic lipid-mobilization effects of glucagon receptor activation. The compound is being developed for obesity and for metabolic dysfunction-associated steatohepatitis (MASH). DA-1726 reported higher-dose Phase 1 results at the EASL Congress 2026 on May 27, 2026, showing a mean 9.1% body weight reduction at Day 54 in the 48 mg cohort with directional improvements in FibroScan liver-fat and stiffness measures versus placebo. Phase 1 Part 3 titration studies are ongoing.

Mechanism of Action

DA-1726 is an oxyntomodulin-analogue dual agonist. Endogenous oxyntomodulin is a 37-amino-acid post-translational product of preproglucagon released from intestinal L-cells; it binds both GLP-1R (driving insulin secretion, slowed gastric emptying, and central appetite suppression) and GCGR (driving hepatic glucose output and, more relevantly here, increased basal energy expenditure and hepatic lipid utilization). DA-1726 retains balanced agonism at both receptors. The GLP-1R component delivers the appetite-suppression mechanism familiar from semaglutide and tirzepatide; the GCGR component is intended to add a second weight-loss lever via thermogenesis and to mobilize hepatic triglyceride, which is the proposed mechanism for the observed reductions in FibroScan controlled attenuation parameter (CAP, a liver-fat surrogate) and vibration-controlled transient elastography (VCTE, a liver-stiffness surrogate).

Potential Benefits

• Mean -6.1% body weight at Day 26 and -9.1% at Day 54 in the 48 mg Phase 1 cohort (no plateau through Week 8)
• Mean -5.8 cm waist circumference at Day 26 and -9.8 cm at Day 54
• FibroScan CAP -20.0 dB/m vs +24.0 dB/m placebo (directional liver-fat improvement)
• FibroScan VCTE liver stiffness -10.3% vs +13.8% placebo (directional liver-stiffness improvement)
• Directional improvement in FibroScan-AST (FAST) score, a composite MASH surrogate
• Once-weekly subcutaneous dosing convenient relative to daily oral GLP-1s
• No clinically meaningful changes in heart rate or QTcF despite glucagon receptor agonism

Research Dosage Notes

The following reflects doses used in published research studies. This is not medical advice.

Investigational only. Phase 1 used 48 mg once-weekly subcutaneous without titration over 4 weeks, with an optional 4-week extension at the same dose.

Routes of Administration

Read our full Routes of Administration Guide for detailed comparison of all delivery methods.

Reconstitution

Amino Acid Sequence

Side Effects & Safety

• Gastrointestinal (mild-to-moderate, transient) without dose titration
• Watch: glucagon receptor activation can in principle raise heart rate and increase hepatic glucose output — Phase 1 saw no clinically meaningful HR or QTcF changes at 48 mg, but longer studies are needed
• Standard incretin-class watch items: nausea, decreased appetite, fatigue

Pharmacokinetics

Synergistic Compounds

The following compounds have been studied alongside DA-1726 for potential complementary or synergistic effects:

Related Peptides

Learn More

References & Further Reading

• MetaVia Presents Higher-Dose Phase 1 Results for DA-1726 at EASL Congress 20262026
• MetaVia to Present DA-1726 Late-Breaking Poster at EASL Congress 20262026